Omalizumab
Bronchodilator & Anti-asthma Preps: Orals/Parenterals · Monoclonal antibody
Indications
As add-on therapy in severe persistent allergic IgE mediated asthma. Chronic idiopathic urticaria.
Dosage
Adults: By SC inj. According to IgE levels; See product literature. Chronic idiopathic urticaria: SC inj: 150 or 300 mg every 4 wks. Children: Not recommended.
Administration
For SC inj only. Doses > 150 mg should be divided over more than one site. May take 5-10 seconds to administer. Reconstitution: Reconstitute using SWFI and allow 15 to 20 mins (on average) for lyophilized product to dissolve. Draw 1.4 mL sterile water for injection into a 3 mL syringe with a 1 inch 18G needle. Place the vial upright and inject sterile water into vial using aseptic technique. Gently swirl upright vial for about 1 min to evenly wet powder. Don’t shake. Every 5 mins, gently swirl for 5 to 10 seconds until solution contains no gel-like particles. Discard if powder takes longer than 40 mins to dissolve and start with a new vial. Once reconstituted, solution should be clear or slightly opalescent and may have a few small bubbles or foam around edge of vial. Stability: Store under refrigerated conditions, 2°C-8°C (36°F-46°F).
Adverse Effects
Inj site reactions, headache, anaphylactic reactions, abdominal pain, pyrexia, serum sickness, Churg-Strauss syndrome, systemic eosinophilia, vasculitis (discontinue if severe).
Risk Factor (Pregnancy/Lactation)
Pregnancy: No evidence of risk in humans. Lactation: Caution advised or effect undetermined. Contraindications: Acute asthma, acute bronchospasm, status asthmatic. Precautions: Hyper-immunoglobulin E syndrome, allergic bronchopulmonary aspergillosis, auto- immune disease, immune complex-mediated conditions, susceptibility to helminths infection, renal or hepatic impairment, diabetes. Withdraw concomitant corticosteroids slowly. Advise patients to report symptoms of serum sickness. Latex allergy.
Interactions
Antiparasitics.
Advice to Patient
If you are self-administering this medication, follow directions for reconstitution, administration, storage, needle and syringe disposal. Contact prescriber if there is difficulty in breathing, skin rash, chest pain, reaction at injection site (redness, swelling, itching). To relieve joint pain, bone pain or ear pain, consult prescriber for pain-killer. Regularly follow-up visits with prescriber.
Pharmacokinetics
Onset of action: Response to therapy: Approx. 12-16 wks. Absorption: Slow following SC injection. Metabolism: Degradation of IgG and omalizumab: IgE complexes by reticuloendothelial system and endothelial cells in the liver. Bioavailability: 62%. Half-life elimination: 26 days (asthma patients); 24 days (chronic idiopathic urticarial patients). Time to peak: 7-8 days. Excretion: Primarily via hepatic degradation; intact IgG may be secreted in bile.
Brands with this active ingredient
Compiled by Healify Pharmacy from published drug references. How we compile it →
Always consult a pharmacist or doctor.